Kilannin Krysiak, Ph.D.,  McDonnell Genome Institute

As part of the Griffith Lab, Dr. Krysiak’s work focuses on the analysis and interpretation of genomic and transcriptomic cancer sequencing data. Her primary interest is in the use of these data to improve the current standards of patient care. She is involved in the comprehensive analysis of cancer patient cohorts as well as small cohort and “n-of-1” studies. In collaboration with the Genomics Tumor Board at Washington University School of Medicine, she has led the analysis of genomic case studies, gaining insight into the molecular underpinnings of the atypical clinical presentation of these cancers. Since joining the McDonnell Genome Institute in 2014, she has also been part of a team of developers and researchers creating CIViC, an open-source, community driven database for the interpretation of clinically-relevant genetic variants that are observed in cancer.

Dr. Krysiak received a B.S. in Biology from the University of Illinois Urbana-Champaign in 2006, where she stayed on as a research technician and focused on improving the efficacy of the anti-tumor properties of bisphosphonates before pursuing her doctorate. In 2014, Dr. Krysiak received her Ph.D. in Molecular Genetics and Genomics from Washington University in St. Louis for work investigating the role of HSPA9 in hematopoiesis and myelodysplastic syndrome.


Publications

K. Krysiak, JF. Tibbitts, J. Shao, T. Liu, M. Ndonwi, MJ. Walter. “Reduced levels of Hspa9 attenuate Stat5 activation in mouse B cells.” Exp Hematol. 2015 Apr;43(4):319-30. PMID:25550197

TA. Graubert, D. Shen, L. Ding, T. Okeyo-Owuor, CL. Lunn, J. Shao, K. Krysiak, CC. Harris, DC. Koboldt, DE. Larson, MD. McLellan, DJ. Dooling, RM. Abbott, RS. Fulton, H. Schmidt, J. Kalicki-Veizer, M. O’Laughlin, M. Grillot, J. Baty, S. Heath, JL. Frater, T. Nasim, DC. Link, MH. Tomasson, P. Westervelt, JF. DiPersio, ER. Mardis, TJ. Ley, RK. Wilson, and MJ. Walter. “Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes.” Nat Gen. 2011 Dec 11;44(1):53-7. PMID:22158538

TH. Chen, A. Kambal, K. Krysiak, MA. Walshauser, G. Raju, JF. Tibbitts, MJ. Walter. “Knockdown of Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice.” Blood. 2011;117(5):1530-1539. PMID:21123823

Y. Zhang, R. Cao, F. Yin, FY. Lin, H. Wang, K. Krysiak, JH. No, D. Mukkamala, K. Houlihan, J. Li, CT. Morita, E. Oldfield. “Lipophilic pyridinium bisphosphonates: potent gammadelta T cell stimulators.” Angew Chem Int Ed Engl. 2010 Feb 1;49(6):1136-8. PMID:20039246

Y. Zhang, R. Cao, F. Yin, MP. Hudock, RT. Guo, K. Krysiak, S. Mukherjee, YG. Gao, H. Robinson, Y. Song, JH. No, K. Bergan, A. Leon, L. Cass, A. Goddard, TK. Chang, FY. Lin, E. Van Beek, S. Papapoulos, AH. Wang, T. Kubo, M. Ochi, D. Mukkamala, E. Oldfield, “Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation.” J Am Chem Soc. 2009 Apr 15;131(14):5153-62. PMID:19309137

Y. Song, JM. Chan, Z. Tovian, A. Secrest, E. Nagy, K. Krysiak, K. Bergan, MA. Parniak, E. Oldfield. “Bisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3’-azido,3’-deoxythymidine: A QSAR investigation.” Bioorg Med Chem. 2008 Oct 1;16(19):8959-67. PMID:18789701

Y. Zhang, M. Hudock, K. Krysiak, R. Cao, K. Bergan, F. Yin, A. Leon, E. Oldfield. “Activity of sulfonium bisphosphonates on tumor cell lines.” J Med Chem. 2007 Nov 29;50(24):6067-79. PMID:17963374

Publications

title citation publication date
CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer Nat Genet. 2017 Jan 31;49(2):170-174. doi: 10.1038/ng.3774. 2017-01-31
Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood. 2017 Jan 26;129(4):473-483. doi: 10.1182/blood-2016-07-729954. Epub 2016 Nov 14. 1970-08-22
Truncating Prolactin Receptor Mutations Promote Tumor Growth in Murine Estrogen Receptor-Alpha Mammary Carcinomas. Cell Rep. 2016 Sep 27;17(1):249-60. doi: 10.1016/j.celrep.2016.08.076. 1970-08-22
CIViC: A knowledgebase for expert-crowdsourcing the clinical interpretation of variants in cancer doi: http://dx.doi.org/10.1101/072892
Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia Exp Hematol. 2016 Jul;44(7):603-13. doi: 10.1016/j.exphem.2016.04.011. Epub 2016 May 13 2016-07-01
A genomic analysis of Philadelphia chromosome-negative AML arising in patients with CML Blood Cancer J. 2016 Apr 8;6:e413. doi: 10.1038/bcj.2016.18 2016-04-08
A genomic case study of mixed fibrolamellar hepatocellular carcinoma. Ann Oncol. 2016 Mar 30. pii: mdw135. [Epub ahead of print] 2016-03-30
DGIdb 2.0: mining clinically relevant drug-gene interactions. Nucleic Acids Res. 2015 Nov 3. pii: gkv1165. [Epub ahead of print] 2015-11-03